百克生物：鼻喷流感减毒活疫苗上市许可申请获得批准的

Group 1 - The core point of the article is that Baike Biotech (688276.SH) has received the Drug Registration Certificate for a nasal spray live attenuated influenza vaccine from the National Medical Products Administration [1] - The newly approved vaccine simulates natural infection by the influenza virus through nasal administration, creating an immune barrier in the respiratory tract against influenza virus invasion [1] - This vaccine is an upgraded liquid formulation from the previously marketed lyophilized nasal spray live attenuated influenza vaccine, eliminating the need for reconstitution during use, making it more convenient for administration [1] - The target population for this vaccine is individuals aged 3 to 17 years [1]